You just read:

Glenmark Receives Orphan Drug Designation for GBR 1342, a Bispecific Antibody Candidate Under Evaluation for the Treatment of Multiple Myeloma

News provided by

Glenmark Pharmaceuticals

Sep 16, 2019, 08:00 ET